The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Successful autologous hematopoietic stem cell (AHSC) mobilization with salvage etoposide (VP16)-ifosfamide-platinum (VIP) followed by high-dose chemotherapy (HDC) and AHSC transplantation (AHSCT) in relapsed malignancies: preliminary single center experience.
C. Kosmas
No relevant relationships to disclose
A. Athanasopoulos
No relevant relationships to disclose
P. Politis
No relevant relationships to disclose
T. Papachrysanthou
No relevant relationships to disclose
T. Daladimos
No relevant relationships to disclose
A. Papadaki
No relevant relationships to disclose
E. Panagiotidi
No relevant relationships to disclose
D. Moschovis
No relevant relationships to disclose
N. Ziras
No relevant relationships to disclose
A. Karabelis
No relevant relationships to disclose
N. Mylonakis
No relevant relationships to disclose